Jiangsu Hengrui Medicine
600276.SS
NZ$12.82
Share price
2.03%
Change (1 day)
36.52%
Change (1 year)
Categories
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics
Earnings for Jiangsu Hengrui Medicine (600276.SS)
Earnings in 2025 (TTM): NZ$1.82 Billion
According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$4.04 Billion. In 2024 the company made an earning of NZ$1.63 Billion, an increase over its 2023 earnings that were of NZ$1.08 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | NZ$1.82 B | 11.22% |
| 2024 | NZ$1.63 B | 50.69% |
| 2023 | NZ$1.08 B | 11.4% |
| 2022 | NZ$0.97 B | -13.65% |
| 2021 | NZ$1.12 B | -34.21% |
| 2020 | NZ$1.71 B | 15.95% |
| 2019 | NZ$1.48 B | 33.03% |
| 2018 | NZ$1.11 B | 20.89% |
| 2017 | NZ$0.92 B | 23.89% |
| 2016 | NZ$0.74 B | 11.21% |
| 2015 | NZ$0.66 B | 39.5% |
| 2014 | NZ$0.47 B | 20.61% |
| 2013 | NZ$0.39 B | 11.46% |
| 2012 | NZ$0.35 B | 29.7% |
| 2011 | NZ$0.27 B | 31.16% |
| 2010 | NZ$0.20 B | 27.92% |
| 2009 | NZ$0.16 B | 5.8% |
| 2008 | NZ$0.15 B | 79.95% |
| 2007 | NZ$86.04 M | 32.89% |
| 2006 | NZ$64.75 M | 38.19% |
| 2005 | NZ$46.85 M | 21.56% |
| 2004 | NZ$38.54 M | 13.95% |
| 2003 | NZ$33.82 M | 38.06% |
| 2002 | NZ$24.5 M |